<DOC>
	<DOCNO>NCT01497522</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety vildagliptin 50 mg bid add-on therapy metformin Japanese patient T2DM . This study conduct support registration fixed-dose combination vildagliptin metformin treatment Type 2 diabetes mellitus ( T2DM ) Japan .</brief_summary>
	<brief_title>Efficacy Safety Vildagliptin add-on Therapy Metformin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients type 2 diabetes inadequately control diet , exercise oral antidiabetic therapy . HbA1c range 7.010.0 % Body mass index range 2035 kg/m2 Type 1 diabetes , diabetes result pancreatic injury , secondary form diabetes Significant heart diseases Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Vildagliptin</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>HbA1c</keyword>
	<keyword>Fasting plasma glucose</keyword>
</DOC>